Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ENRIQUE A MENDEZ

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1174605646
CMS profile
595852
Location
LAKE CHARLES, LA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$4,133.49

278 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $4,093.49 277
Consulting Fee $40.00 1

By paying entity

PY2019 · entire year · sorted by reported total

Page 2 of 6; records 51–100 of 278 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ENRIQUE A MENDEZ

NPI 1174605646 · CMS profile ID 595852

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

LAKE CHARLES, LA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 6; records 51–100 of 278 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1174605646?year=2019&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ENRIQUE A MENDEZ, NPI 1174605646, CMS profile ID 595852. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 6; records 51–100 of 278 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1174605646?year=2019&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). ENRIQUE A MENDEZ, NPI 1174605646, CMS profile ID 595852. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 6; records 51–100 of 278 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1174605646?year=2019&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
ENRIQUE A MENDEZ, NPI 1174605646, CMS profile ID 595852, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 6; records 51–100 of 278 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1174605646?year=2019&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

278 matching records · $4,133.49 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 278 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 278.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Biotech, Inc. $19.7210/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658592399 CMS
Lilly USA, LLC $11.7310/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657804837 CMS
Novartis Pharmaceuticals Corporation $22.3010/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659823353 CMS
E.R. Squibb & Sons, L.L.C. $17.8710/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651281841 CMS
Amgen Inc. $18.6610/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662331233 CMS
MEDEXUS PHARMA, INC. $2.2110/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673860837 CMS
UCB, Inc. $0.5510/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688306009 CMS
UCB, Inc. $9.8710/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688306011 CMS
Mallinckrodt Enterprises LLC $24.2110/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704756853 CMS
Horizon Therapeutics plc $10.6210/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 691444873 CMS
AbbVie, Inc. $18.7909/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647857665 CMS
Amgen Inc. $3.8509/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662331231 CMS
GlaxoSmithKline, LLC. $16.6809/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671271883 CMS
Novartis Pharmaceuticals Corporation $20.5609/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659823355 CMS
E.R. Squibb & Sons, L.L.C. $15.5809/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651281833 CMS
AbbVie, Inc. $13.6809/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647857629 CMS
Horizon Therapeutics plc $26.0009/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 691444869 CMS
Amgen Inc. $12.1109/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662331255 CMS
PFIZER INC. $3.1709/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672549157 CMS
UCB, Inc. $15.4309/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688318343 CMS
Amgen Inc. $8.5909/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662331203 CMS
GENZYME CORPORATION $85.9409/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694183731 CMS
MEDEXUS PHARMA, INC. $13.6309/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673860833 CMS
MEDEXUS PHARMA, INC. $2.6709/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673860835 CMS
PFIZER INC. $4.6109/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672782365 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $22.1909/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700472267 CMS
GENZYME CORPORATION $18.0009/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694148357 CMS
Mallinckrodt Enterprises LLC $21.9609/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704756851 CMS
PFIZER INC. $6.7309/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672958753 CMS
AbbVie, Inc. $11.6009/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647857657 CMS
Amgen Inc. $26.3708/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662331253 CMS
Horizon Therapeutics plc $16.1808/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 691444865 CMS
MEDEXUS PHARMA, INC. $9.7808/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673860831 CMS
PFIZER INC. $3.7308/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672634475 CMS
PFIZER INC. $18.6008/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672521323 CMS
E.R. Squibb & Sons, L.L.C. $14.3908/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651281819 CMS
AbbVie, Inc. $20.3208/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647857641 CMS
Lilly USA, LLC $13.7108/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657808273 CMS
MEDEXUS PHARMA, INC. $9.0408/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673860847 CMS
GENZYME CORPORATION $18.8608/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694104467 CMS
Novartis Pharmaceuticals Corporation $15.2708/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659823347 CMS
AbbVie, Inc. $17.4008/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647857627 CMS
Amgen Inc. $15.6408/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662331229 CMS
E.R. Squibb & Sons, L.L.C. $3.7408/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651281817 CMS
Horizon Therapeutics plc $11.7408/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 691444861 CMS
Mallinckrodt Enterprises LLC $16.0308/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704756849 CMS
PFIZER INC. $7.0208/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672547953 CMS
Daiichi Sankyo Inc. $15.1808/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695328185 CMS
UCB, Inc. $15.2708/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688302903 CMS
AbbVie, Inc. $1.4808/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647857655 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $4,133.49 278
PY2020 $2,031.84 123
PY2021 $3,005.79 188
PY2022 $3,424.76 190
PY2023 $5,210.28 209
PY2024 $3,402.85 157
PY2025 $7,678.36 169

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $688,026.26 107
PY2024 Recipient $104.58 1
PY2024 Principal investigator $384,938.20 19
PY2023 Principal investigator $354,535.61 53
PY2022 Recipient $1,471.00 1
PY2022 Principal investigator $185,615.31 55
PY2021 Principal investigator $125,173.31 87
PY2020 Recipient $76.50 1
PY2020 Principal investigator $51,308.47 4
PY2019 Recipient $24,973.00 1
PY2019 Principal investigator $106,011.68 3

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

107 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 UCB SA $7,000.00 12/19/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH INC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DAPIROLIZUMAB PEGOL IN STUDY PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 1246656808
Principal investigator 1 ABBVIE INC. $100.00 12/04/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH INC
A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis No dispute reported 06/30/2026 1202528756
Principal investigator 1 ABBVIE INC. $2,635.00 11/20/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH INC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202524954
Principal investigator 1 ARGENX US, INC. $3,044.00 11/20/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144826
Principal investigator 1 ARGENX US, INC. $576.00 11/20/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144828
Principal investigator 1 ARGENX US, INC. $5,289.00 11/20/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144857
Principal investigator 1 ARGENX US, INC. $1,613.00 11/20/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144861
Principal investigator 1 ARGENX US, INC. $1,613.00 11/20/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144865
Principal investigator 1 ARGENX US, INC. $5,323.00 11/20/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144870
Principal investigator 1 ABBVIE INC. $100.00 11/05/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH INC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202522711
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $425.59 10/22/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH INC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naive Subjects With Active Psoriatic Arthritis II (INSPIRE 2) No dispute reported 06/30/2026 1246430624
Principal investigator 1 ARGENX US, INC. $1,659.00 10/02/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144821
Principal investigator 1 ARGENX US, INC. $576.00 10/02/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144832
Principal investigator 1 ARGENX US, INC. $576.00 10/02/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144837
Principal investigator 1 ARGENX US, INC. $576.00 10/02/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144841
Principal investigator 1 ARGENX US, INC. $576.00 10/02/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144845
Principal investigator 1 ARGENX US, INC. $576.00 10/02/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144849
Principal investigator 1 ARGENX US, INC. $1,613.00 10/02/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144853
Principal investigator 1 ARGENX US, INC. $5,289.00 10/02/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144875
Principal investigator 1 ARGENX US, INC. $1,540.00 10/02/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144880
Principal investigator 1 Amgen Inc. $1,324.11 09/24/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH INC
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity No dispute reported 06/30/2026 1246638793
Principal investigator 1 ARGENX US, INC. $238.75 09/03/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237145196
Principal investigator 1 ARGENX US, INC. $56.40 09/03/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237145214
Principal investigator 1 ARGENX US, INC. $2.80 09/03/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237145217
Principal investigator 1 ARGENX US, INC. $132.50 09/03/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237145232
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,412.45 08/21/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH INC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223284509
Principal investigator 1 Amgen Inc. $5,234.08 08/19/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH INC
A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of HZN-1116 in Participants With Sjgren's Syndrome No dispute reported 06/30/2026 1246638791
Principal investigator 1 Novartis Pharmaceuticals Corporation $22,001.70 08/19/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH
A randomized, double-blind, placebo-controlled extension study to assess the long-term safety and tolerability of ianalumab in patients with systemic lupus erythematosus (SIRIUS-SLE extension) No dispute reported 06/30/2026 1190310240
Principal investigator 1 ARGENX US, INC. $4,089.00 08/13/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237145178
Principal investigator 1 ARGENX US, INC. $5,782.00 08/13/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237145183
Principal investigator 1 ARGENX US, INC. $3,044.00 08/13/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237145188
Principal investigator 1 ARGENX US, INC. $1,613.00 08/13/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237145192
Principal investigator 1 IDORSIA PHARMACEUTICALS US INC $808.00 08/07/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
A Phase 3, multicenter, open-label, single-arm, extension study to evaluate the long-term safety and tolerability of cenerimod in adult subjects with moderate-to-severe systemic lupus erythematosus (SLE) on top of background therapy No dispute reported 06/30/2026 1243524899
Principal investigator 1 ABBVIE INC. $12,200.00 08/06/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH INC
A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis No dispute reported 06/30/2026 1202503251
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,412.45 08/01/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH INC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223283437
Principal investigator 1 ARGENX US, INC. $1,659.00 07/25/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237145169
Principal investigator 1 ARGENX US, INC. $1,540.00 07/25/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237145174
Principal investigator 1 Eli Lilly and Company $13,841.00 07/22/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH INC
A PHASE 4, PROSPECTIVE, OPEN-LABEL, SINGLE-ARM STUDY TO ASSESS THE EFFECTIVENESS OF TIRZEPATIDE AFTER INITIATION OF IXEKIZUMAB IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OVERWEIGHT OR OBESITY IN CLINICAL PRACTICE No dispute reported 06/30/2026 1187880157
Principal investigator 1 Eli Lilly and Company $5,370.00 07/08/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH INC
A PHASE 2B DOUBLE BLIND PLACEBO CONTROLLED STUDY TO EVALUATE PERESOLIMAB IN ADULT PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187874191
Principal investigator 1 ARGENX US, INC. $95.50 07/01/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237145200
Principal investigator 1 ARGENX US, INC. $37.60 07/01/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237145204
Principal investigator 1 ARGENX US, INC. $2.10 07/01/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237145209
Principal investigator 1 ARGENX US, INC. $143.20 07/01/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237145222
Principal investigator 1 ARGENX US, INC. $53.00 07/01/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237145227
Principal investigator 1 ARGENX US, INC. $4,794.90 06/23/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144815
Principal investigator 1 ARGENX US, INC. $4,089.00 06/23/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144818
Principal investigator 1 Eli Lilly and Company $56,064.00 06/23/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH INC
A PHASE 2A, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3541860 IN ADULT PARTICIPANTS WITH MODERATELY-TO-SEVERELY ACTIVE RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187875059
Principal investigator 1 ARGENX US, INC. $1.75 06/18/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144885
Principal investigator 1 ARGENX US, INC. $3.15 06/18/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144888
Principal investigator 1 ARGENX US, INC. $132.50 06/18/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144894
Principal investigator 1 ARGENX US, INC. $13.25 06/18/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144898
Principal investigator 1 ARGENX US, INC. $75.20 06/18/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144902
Principal investigator 1 ARGENX US, INC. $143.20 06/18/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144906
Principal investigator 1 ARGENX US, INC. $35.80 06/18/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144910
Principal investigator 1 ARGENX US, INC. $71.60 06/18/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144913
Principal investigator 1 ARGENX US, INC. $286.50 06/18/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144917
Principal investigator 1 ARGENX US, INC. $5.25 06/18/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144921
Principal investigator 1 ARGENX US, INC. $2.80 06/18/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144927
Principal investigator 1 ARGENX US, INC. $77.40 06/18/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144931
Principal investigator 1 ARGENX US, INC. $155.25 06/18/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144934
Principal investigator 1 ARGENX US, INC. $103.50 06/18/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144938
Principal investigator 1 ARGENX US, INC. $64.05 06/18/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144942
Principal investigator 1 ARGENX US, INC. $214.80 06/18/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144945
Principal investigator 1 ARGENX US, INC. $668.50 06/18/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144949
Principal investigator 1 ARGENX US, INC. $5.60 06/18/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144952
Principal investigator 1 ARGENX US, INC. $21.35 06/18/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144955
Principal investigator 1 ARGENX US, INC. $21.35 06/18/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144959
Principal investigator 1 ARGENX US, INC. $1.05 06/18/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144963
Principal investigator 1 ARGENX US, INC. $477.50 06/18/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144967
Principal investigator 1 ARGENX US, INC. $143.25 06/18/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144972
Principal investigator 1 ARGENX US, INC. $238.75 06/18/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144975
Principal investigator 1 ARGENX US, INC. $85.40 06/18/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144980
Principal investigator 1 Novartis Pharmaceuticals Corporation $19,982.79 06/15/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH
A randomized, double-blind, parallel group, placebo-controlled, multicenter phase 3 trial to evaluate the efficacy, safety and tolerability of ianalumab on top of standard-of-care therapy in patients with active lupus No dispute reported 06/30/2026 1190310242
Principal investigator 1 IDORSIA PHARMACEUTICALS US INC $1,212.00 06/04/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
A Phase 3, multicenter, open-label, single-arm, extension study to evaluate the long-term safety and tolerability of cenerimod in adult subjects with moderate-to-severe systemic lupus erythematosus (SLE) on top of background therapy No dispute reported 06/30/2026 1243524894
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,200.00 05/13/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH INC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223279398
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,310.00 05/13/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH INC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223279400
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,040.00 05/13/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH INC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223279406
Principal investigator 1 IDORSIA PHARMACEUTICALS US INC $6,522.00 05/12/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
A Phase 3, multicenter, open-label, single-arm, extension study to evaluate the long-term safety and tolerability of cenerimod in adult subjects with moderate-to-severe systemic lupus erythematosus (SLE) on top of background therapy No dispute reported 06/30/2026 1243524889
Principal investigator 1 Eli Lilly and Company $45.90 05/08/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH INC
A RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187875755
Principal investigator 1 IDORSIA PHARMACEUTICALS US INC $460.00 04/28/2025 Non-covered Recipient Entity
Advarra, Inc.
A Phase 3, multicenter, open-label, single-arm, extension study to evaluate the long-term safety and tolerability of cenerimod in adult subjects with moderate-to-severe systemic lupus erythematosus (SLE) on top of background therapy No dispute reported 06/30/2026 1243527390
Principal investigator 1 IDORSIA PHARMACEUTICALS US INC $810.00 04/28/2025 Non-covered Recipient Entity
Advarra, Inc.
A Phase 3, multicenter, open-label, single-arm, extension study to evaluate the long-term safety and tolerability of cenerimod in adult subjects with moderate-to-severe systemic lupus erythematosus (SLE) on top of background therapy No dispute reported 06/30/2026 1243527393
Principal investigator 1 IDORSIA PHARMACEUTICALS US INC $1,345.00 04/14/2025 Non-covered Recipient Entity
Advarra, Inc.
A Phase 3, multicenter, open-label, single-arm, extension study to evaluate the long-term safety and tolerability of cenerimod in adult subjects with moderate-to-severe systemic lupus erythematosus (SLE) on top of background therapy No dispute reported 06/30/2026 1243527409
Principal investigator 1 IDORSIA PHARMACEUTICALS US INC $95.00 03/27/2025 Non-covered Recipient Entity
Advarra, Inc.
A Phase 3, multicenter, open-label, single-arm, extension study to evaluate the long-term safety and tolerability of cenerimod in adult subjects with moderate-to-severe systemic lupus erythematosus (SLE) on top of background therapy No dispute reported 06/30/2026 1243527385
Principal investigator 1 Eli Lilly and Company $2,862.07 03/25/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH INC
A PHASE 2A, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3541860 IN ADULT PARTICIPANTS WITH MODERATELY-TO-SEVERELY ACTIVE RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187872619
Principal investigator 1 ARGENX US, INC. $1,248.00 03/24/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237145153
Principal investigator 1 ARGENX US, INC. $1,800.00 03/24/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237145157
Principal investigator 1 ARGENX US, INC. $2,034.00 03/24/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237145161
Principal investigator 1 ARGENX US, INC. $8,000.00 03/24/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237145165
Principal investigator 1 IDORSIA PHARMACEUTICALS US INC $6,234.00 03/24/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
A Phase 3, multicenter, open-label, single-arm, extension study to evaluate the long-term safety and tolerability of cenerimod in adult subjects with moderate-to-severe systemic lupus erythematosus (SLE) on top of background therapy No dispute reported 06/30/2026 1243524884
Principal investigator 1 UCB SA $40,937.00 03/21/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH INC
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND TOLERABILITY OF DAPIROLIZUMAB PEGOL TREATMENT IN STUDY PARTICIPANTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 1246656324
Principal investigator 1 Eli Lilly and Company $11,978.00 03/18/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH INC
A RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187875417
Principal investigator 1 IDORSIA PHARMACEUTICALS US INC $90.00 03/17/2025 Non-covered Recipient Entity
Advarra, Inc.
A Phase 3, multicenter, open-label, single-arm, extension study to evaluate the long-term safety and tolerability of cenerimod in adult subjects with moderate-to-severe systemic lupus erythematosus (SLE) on top of background therapy No dispute reported 06/30/2026 1243527399
Principal investigator 1 IDORSIA PHARMACEUTICALS US INC $810.00 03/17/2025 Non-covered Recipient Entity
Advarra, Inc.
A Phase 3, multicenter, open-label, single-arm, extension study to evaluate the long-term safety and tolerability of cenerimod in adult subjects with moderate-to-severe systemic lupus erythematosus (SLE) on top of background therapy No dispute reported 06/30/2026 1243527403
Principal investigator 1 ABBVIE INC. $11,350.00 03/07/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH INC
M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202460666
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $10,000.00 02/25/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH INC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223275543
Principal investigator 1 IDORSIA PHARMACEUTICALS US INC $95.00 02/24/2025 Non-covered Recipient Entity
Advarra, Inc.
A Phase 3, multicenter, open-label, single-arm, extension study to evaluate the long-term safety and tolerability of cenerimod in adult subjects with moderate-to-severe systemic lupus erythematosus (SLE) on top of background therapy No dispute reported 06/30/2026 1243527414
Principal investigator 1 IDORSIA PHARMACEUTICALS US INC $13,970.00 02/19/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
A Phase 3, multicenter, open-label, single-arm, extension study to evaluate the long-term safety and tolerability of cenerimod in adult subjects with moderate-to-severe systemic lupus erythematosus (SLE) on top of background therapy No dispute reported 06/30/2026 1243524879
Principal investigator 1 AstraZeneca UK Limited $9,765.40 02/12/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH
A Phase I-III Randomized Double blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156-AZD3152 for Pre exposure Prophylaxis of COVID 19 in Participants with Conditions Causing Immune Impairment No dispute reported 06/30/2026 1185543464
Principal investigator 1 Novartis Pharmaceuticals Corporation $35,105.72 02/05/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH
A randomized, double-blind, placebo-controlled extension study to assess the long-term safety and tolerability of ianalumab in patients with systemic lupus erythematosus (SIRIUS-SLE extension) No dispute reported 06/30/2026 1190308018
Principal investigator 1 Eli Lilly and Company $3,718.41 01/27/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH INC
AN ADAPTIVE PHASE 2A/2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY3871801 IN ADULT PARTICIPANTS WITH MODERATELY-TO-SEVERELY ACTIVE RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187872617
Principal investigator 1 Eli Lilly and Company $1,858.82 01/27/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH INC
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187875061
Principal investigator 1 Eli Lilly and Company $114,981.00 01/21/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH INC
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187875751
Principal investigator 1 IDORSIA PHARMACEUTICALS US INC $2,180.70 01/17/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
A Phase 3, multicenter, open-label, single-arm, extension study to evaluate the long-term safety and tolerability of cenerimod in adult subjects with moderate-to-severe systemic lupus erythematosus (SLE) on top of background therapy No dispute reported 06/30/2026 1243524875
Principal investigator 1 UCB SA $12,661.07 01/17/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH, INC.
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DAPIROLIZUMAB PEGOL IN STUDY PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 1246657443
Principal investigator 1 Novartis Pharmaceuticals Corporation $41,896.00 01/14/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH
A Randomized, Double-blind, Placebo-controlled Multicenter Phase 3 Study to Evaluate Efficacy, Safety and Tolerability of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2) No dispute reported 06/30/2026 1190308020
Principal investigator 1 Eli Lilly and Company $122,452.00 01/07/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH INC
AN ADAPTIVE PHASE 2A/2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY3871801 IN ADULT PARTICIPANTS WITH MODERATELY-TO-SEVERELY ACTIVE RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187872253
Principal investigator 1 UCB SA $4,187.50 01/02/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH INC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DAPIROLIZUMAB PEGOL IN STUDY PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 1246659585